X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence

By Jackie McRae  |    November 24, 2020
Systemic racism is as real as any disease, and our industry is not immune. This summer, in the wake of a national outcry for racial and social justice, our industry offered a firm stance – ...   Read More

Committing to diversity, equity and inclusion: A call to action for clinical trials

By Guest Contributor  |    November 19, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds

By Gabby Migliara  |    November 19, 2020
A new analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment when they faced an unexpectedly high...   Read More

An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb

By Stephen J. Ubl  |    November 18, 2020
This year our industry has worked tirelessly to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. At the same...   Read More

Just released: PhRMA members’ new clinical trial diversity principles

By Richard Moscicki, M.D.  |    November 18, 2020
Yesterday, PhRMA published first ever industry-wide principles on clinical trial diversity, a new chapter in the already existing “Principles on Conduct of Clinical Trials & Communication of...   Read More

Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D

By Nicole Longo  |    November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...   Read More

Deep dive: The issues that drove the 2020 vote

By Tom Wilbur  |    November 13, 2020
The 2020 election provided much-needed clarity on the issues that matter most to Americans. Here are three key takeaways:   Read More

Understanding the emergency use authorization process for COVID-19 vaccines

By Richard Moscicki, M.D.  |    November 12, 2020
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop safe and effective vaccines to prevent infection, as well...   Read More

Guest Post: Recognizing America’s Veterans

By Guest Contributor  |    November 11, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New video: See how strong IP protections lead to stronger treatments for patients

By Tom Wilbur  |    November 9, 2020
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP...   Read More

PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

By Nicole Longo  |    November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...   Read More

ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasion

By Guest Contributor  |    November 2, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

U.S. trade policy must prioritize American biopharmaceutical innovation and patient access

By Douglas Petersen  |    November 2, 2020
As the United States biopharmaceutical industry works around the clock to develop vaccines and treatments for COVID-19, it’s more important than ever that international trade policies facilitate...   Read More

Voters want to address the real drivers of health care costs for patients and the system

By Tom Wilbur  |    November 2, 2020
COVID-19 has understandably reshaped the health care conversation surrounding the upcoming election, with roughly one-fifth of voters citing the coronavirus pandemic as the priority issue heading...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates